前列腺癌
- 造模剂
- N-Nitroso-N-methylurea
- 获批药物
- Olaparib
- Enzalutamide
- Talazoparib
- Docetaxel
- Niraparib tosylate
- Darolutamide
- Apalutamide
- Abiraterone Acetate
- Mitoxantrone 2HCl
- Cabazitaxel
- Bicalutamide
- Flutamide
- Relugolix
- Rucaparib Camsylate
- Degarelix acetate
- Nilutamide
- 内分泌疗法 [1]
-
- CYP17A1
- Abiraterone
- Galeterone
- Orteronel
- 靶向骨微环境
-
- Bisphosphonates
- Zoledronic acid
- Risedronate
- Alendronic Acid
- Clodronate disodium tetrahydrate
-
- RANKL
- Denosumab
-
- Calcium Channels [2]
- Thapsigargin
- GSK1016790A
- Suramin sodium salt
- ML-9 HCl
- SKF96365
- CarboxyaMidotriazole orotate
- Diethylstilbestrol
- 5-BDBD
- 化疗
- Docetaxel
- Carboplatin
- Mitoxantrone 2HCl
- Cabazitaxel
- Estramustine phosphate sodium
- 免疫检查点抑制剂
-
- PD-1
- Pembrolizumab
- Nivolumab
-
- PD-L1
- Atezolizumab
- Durvalumab
- Avelumab
-
- CTLA4
- Ipilimumab
- 抗血管生成 [3]
- Bevacizumab
- Sorafenib
- Sunitinib
- Thalidomide
- Cabozantinib
- Cediranib
- Lenalidomide
- Tasquinimod
- Carotuximab
- 靶向PSMA [1]
-
- mAbs
- Rosopatamab
- Pelgifatamab
- 靶向DNA修复 [1]
- 靶向细胞周期 [1]
-
- CDK4/6
- Abemaciclib
- Ribociclib
- Palbociclib
-
- Mutant p53
- Eprenetapopt
- 靶向PI3K/AKT/mTOR [1]
-
- PI3K/mTOR
- Apitolisib
- 靶向表观遗传标志物 [1]
-
- p300/CBP
- Inobrodib
-
- BET bromodomain
- Birabresib
- Mivebresib
- Molibresib
- ZEN-3694
-
- DNMT
- Azacitidine
- Decitabine
- 靶向WNT通路 [1]
-
- WNT-5A
- Foxy-5
-
- VEGF-A
- Bevacizumab
-
- ETAR
- Zibotentan
-
- FGFR
- Erdafitinib
- Masitinib
-
- VEGFR
- Sunitinib
- Cabozantinib
-
- TGFβR1
- Galunisertib
- Anti-TGFb1
-
- SRC
- Dasatinib
- Saracatinib
-
- MEK
- Trametinib
- 相关化合物库
- FDA-approved Anticancer Drug Library
- Anti-cancer Compound Library
- Anti-cancer Compound Library-Ⅱ
- Anti-cancer Metabolism Compound Library
- Cambridge Cancer Compound Library
- Small Molecule Immuno-Oncology Compound Library
- Tyrosine Kinase Inhibitor Library
- PI3K/Akt Inhibitor Library
